EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries - Wikidata - wikimedia - TriplyDB

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

http://www.wikidata.org/entity/Q35046135

about

Prostaglandin E2 induces contraction of liver myofibroblasts by activating EP3 and FP prostanoid receptors Glial and neuronal control of brain blood flow Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors.Endothelial dysfunction and decreased vascular responsiveness in the anterior cruciate ligament-deficient model of osteoarthritis.Prostanoid receptor antagonists: development strategies and therapeutic applications Emerging roles of PGE2 receptors in models of neurological disease.Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood pressure regulation A ceramide analog inhibits cPLA(2) activity and consequent PGE(2) formation in LPS-stimulated macrophages.Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts.A link between smooth muscle cell death and extracellular matrix degradation during vascular atrophy The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache.Signaling via the prostaglandin E₂ receptor EP4 exerts neuronal and vascular protection in a mouse model of cerebral ischemia.Potassium channels and neurovascular coupling.Different Placebos, Different Mechanisms, Different Outcomes: Lessons for Clinical Trials.Contribution of prostanoid signaling to the evolution of spreading depolarization and the associated cerebral blood flow response.Beyond neurovascular coupling, role of astrocytes in the regulation of vascular tone Perivascular nerves and the regulation of cerebrovascular tone.Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice.Neurovascular coupling in humans: Physiology, methodological advances and clinical implications.Role of EP2 and EP4 receptors in airway microvascular leak induced by prostaglandin E2.Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype.Astrocyte regulation of cerebral vascular tone.BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.The complex contribution of NOS interneurons in the physiology of cerebrovascular regulation.COX inhibitors for the treatment of migraine.Hypoxemia, oxygen content, and the regulation of cerebral blood flow Mechanisms Mediating Functional Hyperemia in the Brain.Differential effects of dexamethasone and rosiglitazone in a sephadex-induced model of lung inflammation in rats: possible role of tissue inhibitor of metalloproteinase-3 GW627368X ((N-{2-[4-(4,9-diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]acetyl} benzene sulphonamide): a novel, potent and selective prostanoid EP4 receptor antagonist.Characterization of biosynthesis and modes of action of prostaglandin E2 and prostacyclin in guinea pig mesenteric lymphatic vessels.Functional and molecular characterization of prostaglandin E2 dilatory receptors in the rat craniovascular system in relevance to migraine.Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.Ca(2+) signals evoked by histamine H1 receptors are attenuated by activation of prostaglandin EP2 and EP4 receptors in human aortic smooth muscle cells.Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs.Prostaglandin E2(PGE2) induces headache in healthy subjects.Prostaglandins mediate tonic contraction of the guinea pig and human gallbladder.Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension.Diverse effects of prostaglandin E₂ on vascular contractility.Carbon dioxide-mediated vasomotion of extra-cranial cerebral arteries in humans: a role for prostaglandins?

P2860

Q28569384-F091A268-1D38-4738-899D-37426C145683 Q29620058-05573AC1-426B-414E-90FD-7DA5B14A2DB6 Q33262176-0F4A360C-E2C8-4915-9D3F-582CF7AA274E Q33262584-953B833B-6A24-4756-9760-9EB0196931A4 Q33485483-0E0C1BDB-61F7-4150-A6B5-DED91D961EE2 Q33756150-BD185BE8-8C1E-493C-8443-F10922904E06 Q34281269-318A16EB-6835-45F4-9713-C26418B8E1B9 Q34520481-A23059D1-C47D-4F84-AC7E-47C6A1E2E25E Q34954633-E2B6F476-305A-4267-B449-1214D31894EE Q35036193-9E557F14-48B0-452F-B072-F9C21018270E Q35085903-4CE4F295-2786-4BF3-B548-E837E1DEC3BC Q35214562-0BD94F40-157E-4ED5-8171-836BAAC6F0F6 Q35484819-3AE49782-037C-4B60-BD4C-89E5E90659F6 Q35510178-540C337D-B668-48F9-A2C5-A45888A2E517 Q35832190-60C507DD-40F4-446C-910E-669608EB7F40 Q36099329-197DD090-37B7-4C08-9A9A-0871B0780F3B Q36118847-DE45F1B4-0412-4D87-8487-5DFA1C5AD501 Q36391631-66426010-BCEF-49CD-AB29-338888A6B2D2 Q36535634-005BF6B1-9404-406E-814D-28E219669006 Q36765857-C84BC090-93E9-4CE9-8C5F-87B1E95198C6 Q36796418-016A4730-D527-4284-A64E-6AE865F3E023 Q36842517-104369F8-C850-477A-87F6-1F5BE10B0A92 Q37142749-A97223AB-1124-461F-88DF-D44F53E42ED8 Q37230998-65525E91-6CBF-4C89-A174-2B345F923297 Q38036205-807F4DAE-2CDA-462B-895D-15F32F0A0C66 Q38227997-7AF702BD-0A3D-4738-86DB-9A92D4B129DF Q38671519-B3BF63D0-C371-4C05-B1A1-306154A3D5A6 Q39238290-BEE50376-ADFD-419B-A199-AD55DC54500B Q39257639-F3AE4EE2-72F2-4EAE-B4BF-95935B299E6D Q40294227-4D9C49A2-737F-491D-9094-E52C815482C6 Q42935835-C6EB78CF-B6F3-4E74-9939-27FC5514964A Q42936119-CD87FA6C-A58D-4047-9B41-337E779F84C7 Q42940476-D0D91F84-1CD4-40C5-8ED2-87B261B20510 Q43073261-2379A988-A2DD-4BB0-BCC1-53AF9635B749 Q45926654-830E6629-AC1B-41A7-9FBA-F4EB8488065C Q46136517-95C9771A-92C4-4D4F-9553-95687BF3D28D Q46267351-92919CBC-120A-43B2-B5CD-31B847605907 Q46604316-6BB19697-8723-44AA-AC2B-4AE1D8C36C3B Q46649673-9162C05E-310D-4980-9C7F-D5B2C7EF26D6 Q48237898-0126B1B7-5DE0-45E2-8B58-274198184D44

P2860

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

http://www.wikidata.org/entity/Q35046135

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

@en

type

label

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

@en

prefLabel

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

@en

P1433

Q35046135-401D41D6-62FF-40BA-97A6-5F1D5D6B4E33

P1476

Q35046135-56791060-C839-4804-AFDD-626D7DF64D4C

P2093

Q35046135-42AB5C40-FCF0-4FE4-B06E-0D362BA0F2D3

Q35046135-73071405-3FC4-45C8-B0AF-1124E1FD3D76

Q35046135-73919E31-4A84-406D-9F48-061F0F32CB6F

Q35046135-7C1E155E-1275-4237-864C-F12E3C4EDDD6

Q35046135-9F3E3A41-7FD8-4633-8942-D6D0EB2E1D32

Q35046135-AA0AD5E3-D262-488C-8627-EC8A24D20342

Q35046135-C5589F84-D4A8-482C-B6D4-C89D6F5EEEF0

Q35046135-F924D623-7BBE-4D6E-9B64-9A3FE6BB4450

Q35046135-FF9F1906-70B8-4554-8294-61D9A5F5FA72

P2860

Q35046135-06A51665-412E-42BF-A1B9-584F31353E0D

Q35046135-1364E8FC-1C0B-4EDB-A890-931511160410

Q35046135-1A56D3F0-953A-455C-B402-94DB89F5B7E2

Q35046135-1F10A99D-3588-4F34-B3B7-5914C57DE22E

Q35046135-2A4532A0-8D08-471A-A7FB-A6189CB9CC65

Q35046135-304F0250-F08D-4837-A9E2-517B1D5496FA

Q35046135-331B120A-AD21-40EE-98D6-E75E2206052C

Q35046135-3E141B0D-7FE7-439B-AAA8-F021FAD64FAF

Q35046135-3E739A6A-657B-4FC9-9AC9-AAF8D69AFEE7

Q35046135-4AAF7DEB-CE1A-4936-AFFE-BB73C87AA5EF

P304

Q35046135-A71964BD-C396-4C97-B33C-712338CA5CD8

P31

Q35046135-F163199C-06DD-441D-8FC4-2642DB9F501E

P356

Q35046135-BE2876EF-75E4-4947-BD36-217D711D6749

P407

Q35046135-0365D75F-D0EF-43E5-BF4E-90F174F8AD02

P433

Q35046135-CFEE4574-C0FC-4F23-9AB7-4D35752C0ACF

P478

Q35046135-39C04471-56AB-446B-AC7F-2959E08F5B3E

P50

Q35046135-129E423D-3231-4FA3-A821-57E721902DD8

P577

Q35046135-A1EAFC80-6DD3-4B19-8275-0FE37985AF3D

P5875

Q35046135-8D9A37C8-374E-4E1B-BBA3-91AAD12EA705

P698

Q35046135-F9B2EB68-2CCC-481E-9856-C8C88669F699

P921

Q35046135-E47935C6-10C7-43D3-AF1C-CF0A446E7EAF

P932

Q35046135-54F0D814-8612-46D1-96CB-619BF489A798

P356

P1433

British Journal of Pharmacology

P1476

EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries

@en

P2093

Gordon S Baxter

http://www.w3.org/2001/XMLSchema#string

Kenneth L Clark

http://www.w3.org/2001/XMLSchema#string

Mozam Ali

http://www.w3.org/2001/XMLSchema#string

Nick Tilford

http://www.w3.org/2001/XMLSchema#string

Richard J Davis

http://www.w3.org/2001/XMLSchema#string

Rivka Ravid

http://www.w3.org/2001/XMLSchema#string

Robert A Coleman

http://www.w3.org/2001/XMLSchema#string

Robert L G Sheldrick

http://www.w3.org/2001/XMLSchema#string

Stuart Purbrick

http://www.w3.org/2001/XMLSchema#string

P2860

Characterization of the prostanoid receptor types involved in mediating calcitonin gene-related peptide release from cultured rat trigeminal neurones

International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes

GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro

Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor

Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells

Adaptive cytoprotection mediated by prostaglandin I(2) is attributable to sensitization of CRGP-containing sensory nerves

Some quantitative uses of drug antagonists

Effect of removal of the endothelium on vasocontraction in canine and rabbit basilar arteries.

Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes.

Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial.

P304

580-585

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJP.0705645

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

141

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-01-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8901461

http://www.w3.org/2001/XMLSchema#string

P698

14744815

http://www.w3.org/2001/XMLSchema#string

P921

P932

1574229

http://www.w3.org/2001/XMLSchema#string